These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

376 related articles for article (PubMed ID: 17562501)

  • 1. Emerging and unusual gram-negative infections in cystic fibrosis.
    Davies JC; Rubin BK
    Semin Respir Crit Care Med; 2007 Jun; 28(3):312-21. PubMed ID: 17562501
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Burkholderia and emerging pathogens in cystic fibrosis.
    LiPuma JJ
    Semin Respir Crit Care Med; 2003 Dec; 24(6):681-92. PubMed ID: 16088584
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pan-Resistant Achromobacter xylosoxidans and Stenotrophomonas maltophilia Infection in Cystic Fibrosis Does Not Reduce Survival After Lung Transplantation.
    Lobo LJ; Tulu Z; Aris RM; Noone PG
    Transplantation; 2015 Oct; 99(10):2196-202. PubMed ID: 25856407
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Microbiology of airway disease in a cohort of patients with cystic fibrosis.
    Lambiase A; Raia V; Del Pezzo M; Sepe A; Carnovale V; Rossano F
    BMC Infect Dis; 2006 Jan; 6():4. PubMed ID: 16405721
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identification and antimicrobial susceptibility of Alcaligenes xylosoxidans isolated from patients with cystic fibrosis.
    Saiman L; Chen Y; Tabibi S; San Gabriel P; Zhou J; Liu Z; Lai L; Whittier S
    J Clin Microbiol; 2001 Nov; 39(11):3942-5. PubMed ID: 11682511
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Emerging cystic fibrosis pathogens: incidence and antimicrobial resistance.
    Magni A; Giordano A; Mancini C; Pecoraro C; Varesi P; Quattrucci S; Trancassini M
    New Microbiol; 2007 Jan; 30(1):59-62. PubMed ID: 17319602
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inflammation in Achromobacter xylosoxidans infected cystic fibrosis patients.
    Hansen CR; Pressler T; Nielsen KG; Jensen PØ; Bjarnsholt T; Høiby N
    J Cyst Fibros; 2010 Jan; 9(1):51-8. PubMed ID: 19939747
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pitfalls of polymyxin antimicrobial susceptibility testing of Pseudomonas aeruginosa isolated from cystic fibrosis patients.
    Hogardt M; Schmoldt S; Götzfried M; Adler K; Heesemann J
    J Antimicrob Chemother; 2004 Dec; 54(6):1057-61. PubMed ID: 15509615
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Use of 16S rRNA gene sequencing for identification of "Pseudomonas-like" isolates from sputum of patients with cystic fibrosis].
    Moissenet D; Bingen E; Arlet G; Vu-Thien H
    Pathol Biol (Paris); 2005; 53(8-9):500-2. PubMed ID: 16081224
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Denitrification by cystic fibrosis pathogens - Stenotrophomonas maltophilia is dormant in sputum.
    Kolpen M; Kragh KN; Bjarnsholt T; Line L; Hansen CR; Dalbøge CS; Hansen N; Kühl M; Høiby N; Jensen PØ
    Int J Med Microbiol; 2015 Jan; 305(1):1-10. PubMed ID: 25441256
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification of Pandoraea species by 16S ribosomal DNA-based PCR assays.
    Coenye T; Liu L; Vandamme P; LiPuma JJ
    J Clin Microbiol; 2001 Dec; 39(12):4452-5. PubMed ID: 11724860
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pathophysiology and management of pulmonary infections in cystic fibrosis.
    Gibson RL; Burns JL; Ramsey BW
    Am J Respir Crit Care Med; 2003 Oct; 168(8):918-51. PubMed ID: 14555458
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Use of random amplified polymorphic DNA PCR to examine epidemiology of Stenotrophomonas maltophilia and Achromobacter (Alcaligenes) xylosoxidans from patients with cystic fibrosis.
    Krzewinski JW; Nguyen CD; Foster JM; Burns JL
    J Clin Microbiol; 2001 Oct; 39(10):3597-602. PubMed ID: 11574579
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Multidrug-resistant organisms in cystic fibrosis: management and infection-control issues.
    Waters V; Ratjen F
    Expert Rev Anti Infect Ther; 2006 Oct; 4(5):807-19. PubMed ID: 17140357
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Molecular epidemiology of Burkholderia cepacia, Stenotrophomonas maltophilia, and Alcaligenes xylosoxidans in a cystic fibrosis center.
    Vu-Thien H; Moissenet D; Valcin M; Dulot C; Tournier G; Garbarg-Chenon A
    Eur J Clin Microbiol Infect Dis; 1996 Nov; 15(11):876-9. PubMed ID: 8997562
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identification of Pseudomonas aeruginosa, Burkholderia cepacia complex, and Stenotrophomonas maltophilia in respiratory samples from cystic fibrosis patients using multiplex PCR.
    da Silva Filho LV; Tateno AF; Velloso Lde F; Levi JE; Fernandes S; Bento CN; Rodrigues JC; Ramos SR
    Pediatr Pulmonol; 2004 Jun; 37(6):537-47. PubMed ID: 15114555
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Patient cohorting and infection control.
    Koch C; Frederiksen B; Høiby N
    Semin Respir Crit Care Med; 2003 Dec; 24(6):703-16. PubMed ID: 16088586
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Growth in Stewart's medium is a simple, rapid and inexpensive screening tool for the identification of Burkholderia cepacia complex.
    Vanlaere E; Hansraj F; Vandamme PA; Govan JR
    J Cyst Fibros; 2006 May; 5(2):137-9. PubMed ID: 16386966
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Unusual respiratory bacterial flora in cystic fibrosis: microbiologic and clinical features.
    Beringer PM; Appleman MD
    Curr Opin Pulm Med; 2000 Nov; 6(6):545-50. PubMed ID: 11100967
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Burkholderia cepacia complex bacteria: opportunistic pathogens with important natural biology.
    Mahenthiralingam E; Baldwin A; Dowson CG
    J Appl Microbiol; 2008 Jun; 104(6):1539-51. PubMed ID: 18217926
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.